Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KLK7 | P49862 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29579745 | 1.00 | LMNA (0.57) | LMNASMN1; SMN2KLK7KLK5MAPT | |
| SCHEMBL30859205 | 0.96 | MAPT (0.58) | LMNASMN1; SMN2KLK7KLK5MAPT | |
| SCHEMBL12196508 | 0.96 | MAPT (0.58) | LMNASMN1; SMN2KLK7KLK5MAPT | |
| SCHEMBL18906424 | 0.93 | LMNA (0.51) | LMNASMN1; SMN2KLK7KLK5MAPT | |
| SCHEMBL4857149 | 0.92 | MAPT (0.58) | KLK7KLK5MAPTCTSSCTSL | |
| SCHEMBL13387692 | 0.91 | MAPT (0.58) | KLK7KLK5MAPTCTSSCTSL | |
| SCHEMBL19726709 | 0.91 | LMNA (0.55) | LMNASMN1; SMN2KLK7KLK5MAPT | |
| SCHEMBL12148814 | 0.91 | MAPT (0.62) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL30902797 | 0.91 | MAPT (0.62) | KLK7KLK5MAPTCTSSCTSL | |
| SCHEMBL18906932 | 0.90 | KLK7 (0.54) | LMNASMN1; SMN2KLK7KLK5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059668-A1 | THIOHYDROXYPYRIDINE CHELATES | LUMIPHORE, INC. | 2024-02-22 | — | — | US | disclosed |
| EP-4232029-A1 | THIOHYDROXYPYRIDINE CHELATES | Lumiphore, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022087317-A1 | THIOHYDROXYPYRIDINE CHELATES | LUMIPHORE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059668-A1 | THIOHYDROXYPYRIDINE CHELATES | FTH1, SSB, SLC7A1 | LMNA 4180/4885SMN1; SMN2 2887/4885KLK7 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.